Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis

Keyphrases

• Disease Progression 100%
• Multiple Sclerosis 100%
• Daclizumab 100%
• Anti-CD25 Antibody 100%
• Inflammation Inhibition 100%
• Interferon-β (IFN-β) 40%
• Monotherapy 31%
• Combination Therapy 18%
• Contrast-enhancing Lesions 18%
• Clinical Disability 13%
• High Dose 9%
• Therapeutic Response 9%
• Disease Activity 9%
• Brain Magnetic Resonance Imaging 9%
• Maryland 4%
• Lack of Response 4%
• Neurological Disorders 4%
• Natural Killer Cells 4%
• Phase II Clinical Trial 4%
• CD56 4%
• Adverse Effects 4%
• Inhibition Rate 4%
• Suboptimal Response 4%
• Therapeutic Effect 4%
• Long-term Efficacy 4%
• CD8+ T Cells 4%
• Intravenous Infusion 4%
• Patient Samples 4%
• Therapy Effect 4%
• Systemic Side Effects 4%
• Multiple Sclerosis Treatment 4%
• Bethesda 4%
• Treatment Phase 4%
• Immunological Biomarkers 4%
• Neuroimmunology 4%
• Interferon-β Treatment 4%
• Multiple Sclerosis Exacerbation 4%
• Persistent Disease Activity 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease Exacerbation 100%
• Inflammation 100%
• Multiple Sclerosis 100%
• Daclizumab 100%
• Beta Interferon 45%
• Monotherapy 31%
• Biological Marker 18%
• Combination Therapy 18%
• Disease Activity 13%
• Adverse Event 9%
• Clinical Trial 4%
• Neurologic Disease 4%
• CD8 Antigen 4%
• Therapeutic Effect 4%

Neuroscience

• Multiple Sclerosis 100%
• Daclizumab 100%
• Beta Interferon 45%
• Magnetic Resonance Imaging 9%
• Adverse Effect 9%
• T Cell 4%
• Neurological Disorder 4%
• Natural Killer Cell 4%
• CD8 4%
• Neuroimmunology 4%